Derivatives substituted analogs 18-amino geldanamycin of hydroquinone with cytotoxic activity for the treatment of cancer.

Compound or pharmaceutically acceptable salt thereof having the formula (I) wherein - X is selected from the group consisting of -N (R8) (R9), -N (R8) -C (O) R10, -N ( R8) -C (O) -OR10, -N (R8) -SO2R10, N (R8) -C (O) -NR8R10, -N (R8) -C (S) OR10, -N (R8) -C ( S) -OR10 and -N (R8) -C (S) -NR8R10; wherein R8 and R9 are independently selected from the group consisting of H, (C1-C20) optionally substituted heteroalkyl (C2-C20) optionally substituted (C2-C20) optionally substituted heteroalkenyl, (C2-C20) optionally substituted alkenyl, (C2-C20) optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted, and optionally substituted cycloheteroalkyl or R8 and R9 together with the nitrogen to which they are attached form a ring 4-7 membered heterocyclic optionally substituted; R10 is selected from the group consisting of hydrogen, (C1-C20) optionally substituted heteroalkyl (C1-C20) optionally substituted (C2-C20) optionally substituted heteroalkenyl, (C2-C20) optionally substituted alkenyl, (C2 C20) optionally substituted (C6 C20) optionally substituted heteroaryl (C3-C20) optionally substituted aryl (C7-C20) optionally substituted heteroaryl (C4-C20) optionally substituted (C3-C20) optionally substituted and a cycloheteroalkyl, (C2-C20) optionally substituted; R represents hydrogen, (C1-C6) alkyl or (C1-C6) alkyl or (C6-C10) substituted or unsubstituted or OCOR10; R1 and R2 are each hydrogen or R1 and R2 together form a single bond; R3, R4, Y1, Y2, Y3 are independently selected from the group consisting of H, halogen, -OH, O-alkyl, O-acetyl, -O-aryl, OC (O) R10, -SO2-R10 and -NHR10 or together form oxo (= O), or hydroxylamino or ariloxiimina alcoxiimina, thioketo; or R3 and R4 or Y1 and Y2 form a heterocyclic residue selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, thiazolidinyl, oxazolidinyl, morpholino, piperazinyl, 4alquilpiperidinilo (C1-C4) and N-piperazinyl (C1-C4); alkyl groups and said phenyl and naphthyl may be substituted with one or more residues selected from the group consisting of (C1-C8), halogen, nitro, amino, azido and (C1-C8); R5 is selected from the group consisting of a (C1-C20) optionally substituted heteroalkyl (C1-C20) optionally substituted (C2-C20) optionally substituted heteroalkenyl, (C2-C20) optionally substituted alkenyl, (C2-C20 ) optionally substituted (C6-C20) optionally substituted heteroaryl (C3 C20) optionally substituted aryl (C7-C20) optionally substituted heteroaryl (C4-C20) optionally substituted (C3-C20) optionally substituted cycloheteroalkyl ( C2-C20) optionally substituted, N (R8) (R9); -OR10, -SR10, -N (R8) -C (O) R10, -N (R8) -C (O) -OR10, -N (R8) -C (O) -NR8R10, N (R8) -C (S) OR10, -N (R8) -C (S) -OR10 and -N (R8) -C (S) -NR8R10; R6 is selected from the group consisting of hydrogen, halogen, a (C1-C10) alkyl, (C1-C10), aryl (C6-C10) optionally substituted or unsubstituted; and R7 is selected from the group consisting of hydrogen, (C1-C10) optionally substituted aryl, (C5 C10) optionally substituted acyl and (C1-C10) optionally substituted.